This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Graft Versus Host Disease
and you are
between 18 and 75
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

Open label non-randomized multicenter phase 2 trial with direct individual benefice

Provided treatments

  • Drug: Imatinib Mesylate and Nilotinib

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02891395. The sponsor of the trial is University Hospital, Lille and it is looking for 65 volunteers for the current phase.
Official trial title:
Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host (Graft Versus Host, GVH) Did Not Respond to Imatinib Mesylate.